Pembrolizumab, a monoclonal antibody that inhibits programmed death-1 (PD-1) and modulates immune response, has been shown to provide significant survival benefits when administered as monotherapy in patients harboring a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of more than 50% (6), or when administered in combination with platinum-based chemotherapy regardless of PD-L1 expression (7, 8). The gene discussed is CD274; the disease is neoplasm.